600276: Jiangsu Hengrui Medicine Co., Ltd. - Summary | Jitta

Jiangsu Hengrui Medicine Co., Ltd.

CHN:600276

Price
CN¥44.06
Loss Chance
47.7%
5.52JITTA SCORE
714.16%Over Jitta Line
Jitta Ranking
124 / 479
875 / 5,090
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (47)
Recent Business Performance (63)
Financial Strength (84)
Return to Shareholders (49)
Competitive Advantage (48)
Jitta Signs
Debt LevelLow Long Term Debt
Dividend PayoutEvery year
SG&A to SalesDecreasing
Revenue and EarningRevenue decline from 2019-2022
Operating MarginInconsistent
Recent Business PerformanceEarning decline 9.44% in the last year
Key Stats
Jitta Score
Jitta Line
5.52
714.16%
4.79
> 1,000%
4.74
839.29%
Pharmaceuticals
6.90
34.90%
7.11
57.17%
7.81
32.39%
COMPANY DESCRIPTION
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications. The company was founded in 1970 and is based in Lianyungang, China.